Metagenomi Therapeutics Operating Income 2022-2026 | MGX

Metagenomi Therapeutics operating income from 2022 to 2026. Operating income can be defined as income after operating expenses have been deducted and before interest payments and taxes have been deducted.
Unlock Macrotrends Premium
40 years of data
Faster, ad-free pages
Unlimited data exports
Full-width charts
Metagenomi Therapeutics Annual Operating Income
(Millions of US $)
2025 $-96
2024 $-89
2023 $-78
2022 $-45
2021 $-24
Metagenomi Therapeutics Quarterly Operating Income
(Millions of US $)
2026-06-30 $-29
2026-03-31 $-25
2025-12-31 $-24
2025-09-30 $-23
2025-06-30 $-21
2025-03-31 $-28
2024-12-31 $-21
2024-09-30 $-22
2024-06-30 $-17
2024-03-31 $-29
2023-12-31 $-20
2023-09-30 $-22
2023-06-30 $-18
2023-03-31 $-18
Sector Industry Market Cap Revenue
Medical Medical - Generic Drugs $0.042B $0.025B
Metagenomi Therapeutics Inc. is an in vivo genome editing company capitalizing on its proprietary technologies to create curative genetic medicines for patients. Metagenomi Therapeutics Inc., formerly known as Metagenomi Inc., is based in EMERYVILLE, Calif.
Stock Name Country Market Cap PE Ratio
Teva Pharmaceutical Industries (TEVA) Israel $45.423B 17.88
BridgeBio Pharma (BBIO) United States $13.021B 0.00
Dr Reddy's Laboratories (RDY) India $10.175B 25.94
Aspen Pharmacare (APNHY) South Africa $4.248B 0.00
Supernus Pharmaceuticals (SUPN) United States $2.445B 20.49
Bausch Health Cos (BHC) Canada $2.121B 1.32
Personalis (PSNL) United States $1.717B 0.00
Taysha Gene Therapies (TSHA) United States $1.636B 0.00
Amphastar Pharmaceuticals (AMPH) United States $1.005B 9.45
Assembly Biosciences (ASMB) United States $0.508B 24.48
Sol-Gel Technologies (SLGL) Israel $0.169B 0.00
Evoke Pharma (EVOK) United States $0.019B 0.00
Teligent (TLGT) United States $0.000B 0.00